Evaluating  ||| S:0 E:11 ||| VBG
temsirolimus  ||| S:11 E:24 ||| JJ
activity  ||| S:24 E:33 ||| NN
in  ||| S:33 E:36 ||| IN
multiple  ||| S:36 E:45 ||| JJ
tumors ||| S:45 E:51 ||| NNS
:  ||| S:51 E:53 ||| :
a  ||| S:53 E:55 ||| DT
review  ||| S:55 E:62 ||| NN
of  ||| S:62 E:65 ||| IN
clinical  ||| S:65 E:74 ||| JJ
trials  ||| S:74 E:81 ||| NNS
Activation  ||| S:81 E:92 ||| NNP
of  ||| S:92 E:95 ||| IN
mammalian  ||| S:95 E:105 ||| JJ
target  ||| S:105 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
rapamycin  ||| S:115 E:125 ||| NNS
( ||| S:125 E:126 ||| -LRB-
mTOR ||| S:126 E:130 ||| NNP
)  ||| S:130 E:132 ||| -RRB-
signaling  ||| S:132 E:142 ||| NN
occurs  ||| S:142 E:149 ||| VBZ
in  ||| S:149 E:152 ||| IN
a  ||| S:152 E:154 ||| DT
wide  ||| S:154 E:159 ||| JJ
variety  ||| S:159 E:167 ||| NN
of  ||| S:167 E:170 ||| IN
human  ||| S:170 E:176 ||| JJ
tumors  ||| S:176 E:183 ||| NNS
and  ||| S:183 E:187 ||| CC
can  ||| S:187 E:191 ||| MD
lead  ||| S:191 E:196 ||| VB
to  ||| S:196 E:199 ||| TO
increased  ||| S:199 E:209 ||| VB
susceptibility  ||| S:209 E:224 ||| VBN
to  ||| S:224 E:227 ||| TO
mTOR  ||| S:227 E:232 ||| JJ
inhibitors ||| S:232 E:242 ||| NN
.  ||| S:242 E:244 ||| .
Temsirolimus ||| S:244 E:256 ||| NNP
,  ||| S:256 E:258 ||| ,
a  ||| S:258 E:260 ||| DT
novel  ||| S:260 E:266 ||| NN
analog  ||| S:266 E:273 ||| NN
of  ||| S:273 E:276 ||| IN
rapamycin ||| S:276 E:285 ||| NN
,  ||| S:285 E:287 ||| ,
has  ||| S:287 E:291 ||| VBZ
shown  ||| S:291 E:297 ||| VBN
promising  ||| S:297 E:307 ||| JJ
preclinical  ||| S:307 E:319 ||| NN
and  ||| S:319 E:323 ||| CC
early  ||| S:323 E:329 ||| JJ
clinical  ||| S:329 E:338 ||| JJ
anti-tumor  ||| S:338 E:349 ||| JJ
activity  ||| S:349 E:358 ||| NN
in  ||| S:358 E:361 ||| IN
various  ||| S:361 E:369 ||| JJ
solid  ||| S:369 E:375 ||| JJ
and  ||| S:375 E:379 ||| CC
hematologic  ||| S:379 E:391 ||| JJ
tumor  ||| S:391 E:397 ||| NN
types ||| S:397 E:402 ||| NNS
,  ||| S:402 E:404 ||| ,
either  ||| S:404 E:411 ||| CC
alone  ||| S:411 E:417 ||| RB
or  ||| S:417 E:420 ||| CC
in  ||| S:420 E:423 ||| IN
combination  ||| S:423 E:435 ||| NN
with  ||| S:435 E:440 ||| IN
chemotherapy  ||| S:440 E:453 ||| NN
or  ||| S:453 E:456 ||| CC
other  ||| S:456 E:462 ||| JJ
targeted  ||| S:462 E:471 ||| JJ
agents ||| S:471 E:477 ||| NNS
.  ||| S:477 E:479 ||| .
Randomized  ||| S:479 E:490 ||| JJ
phase  ||| S:490 E:496 ||| NN
III  ||| S:496 E:500 ||| NNP
trials  ||| S:500 E:507 ||| NNS
have  ||| S:507 E:512 ||| VBP
already  ||| S:512 E:520 ||| RB
demonstrated  ||| S:520 E:533 ||| VBN
significant  ||| S:533 E:545 ||| JJ
clinical  ||| S:545 E:554 ||| JJ
benefits  ||| S:554 E:563 ||| NNS
of  ||| S:563 E:566 ||| IN
treatment  ||| S:566 E:576 ||| NN
with  ||| S:576 E:581 ||| IN
single-agent  ||| S:581 E:594 ||| JJ
temsirolimus  ||| S:594 E:607 ||| NN
in  ||| S:607 E:610 ||| IN
advanced  ||| S:610 E:619 ||| JJ
renal  ||| S:619 E:625 ||| JJ
cell  ||| S:625 E:630 ||| NN
carcinoma  ||| S:630 E:640 ||| NNS
and  ||| S:640 E:644 ||| CC
relapsed  ||| S:644 E:653 ||| NNS
and ||| S:653 E:656 ||| CC
/ ||| S:656 E:657 ||| NNP
or  ||| S:657 E:660 ||| CC
refractory  ||| S:660 E:671 ||| JJ
mantle  ||| S:671 E:678 ||| JJ
cell  ||| S:678 E:683 ||| NN
lymphoma ||| S:683 E:691 ||| NN
.  ||| S:691 E:693 ||| .
Other  ||| S:693 E:699 ||| JJ
malignancies  ||| S:699 E:712 ||| NNS
studied  ||| S:712 E:720 ||| VBN
in  ||| S:720 E:723 ||| IN
the  ||| S:723 E:727 ||| DT
phase  ||| S:727 E:733 ||| NN
I  ||| S:733 E:735 ||| PRP
and  ||| S:735 E:739 ||| CC
II  ||| S:739 E:742 ||| NNP
trial  ||| S:742 E:748 ||| NN
settings  ||| S:748 E:757 ||| NNS
include  ||| S:757 E:765 ||| VBP
glioblastoma ||| S:765 E:777 ||| VBN
,  ||| S:777 E:779 ||| ,
breast  ||| S:779 E:786 ||| JJ
cancer ||| S:786 E:792 ||| NN
,  ||| S:792 E:794 ||| ,
endometrial  ||| S:794 E:806 ||| JJ
cancer ||| S:806 E:812 ||| NN
,  ||| S:812 E:814 ||| ,
non-Hodgkin  ||| S:814 E:826 ||| JJ
lymphomas ||| S:826 E:835 ||| NN
,  ||| S:835 E:837 ||| ,
and  ||| S:837 E:841 ||| CC
multiple  ||| S:841 E:850 ||| JJ
myeloma ||| S:850 E:857 ||| NN
.  ||| S:857 E:859 ||| .
This  ||| S:859 E:864 ||| DT
article  ||| S:864 E:872 ||| NN
reviews  ||| S:872 E:880 ||| VBZ
a  ||| S:880 E:882 ||| DT
comprehensive  ||| S:882 E:896 ||| JJ
collection  ||| S:896 E:907 ||| NN
of  ||| S:907 E:910 ||| IN
the  ||| S:910 E:914 ||| DT
clinical  ||| S:914 E:923 ||| JJ
trial  ||| S:923 E:929 ||| NN
results  ||| S:929 E:937 ||| NNS
reported  ||| S:937 E:946 ||| VBD
to  ||| S:946 E:949 ||| TO
date  ||| S:949 E:954 ||| NN
for  ||| S:954 E:958 ||| IN
temsirolimus  ||| S:958 E:971 ||| NN
in  ||| S:971 E:974 ||| IN
various  ||| S:974 E:982 ||| JJ
solid  ||| S:982 E:988 ||| JJ
and  ||| S:988 E:992 ||| CC
hematologic  ||| S:992 E:1004 ||| JJ
malignancies ||| S:1004 E:1016 ||| NN
,  ||| S:1016 E:1018 ||| ,
as  ||| S:1018 E:1021 ||| RB
well  ||| S:1021 E:1026 ||| RB
as  ||| S:1026 E:1029 ||| IN
current  ||| S:1029 E:1037 ||| JJ
strategies  ||| S:1037 E:1048 ||| NNS
being  ||| S:1048 E:1054 ||| VBG
tested  ||| S:1054 E:1061 ||| VBN
in  ||| S:1061 E:1064 ||| IN
ongoing  ||| S:1064 E:1072 ||| JJ
trials ||| S:1072 E:1078 ||| NNS
.  ||| S:1078 E:1080 ||| .
The  ||| S:1080 E:1084 ||| DT
findings  ||| S:1084 E:1093 ||| NNS
with  ||| S:1093 E:1098 ||| IN
temsirolimus  ||| S:1098 E:1111 ||| NN
in  ||| S:1111 E:1114 ||| IN
multiple  ||| S:1114 E:1123 ||| JJ
tumors  ||| S:1123 E:1130 ||| NNS
provide  ||| S:1130 E:1138 ||| VBP
a  ||| S:1138 E:1140 ||| DT
valuable  ||| S:1140 E:1149 ||| JJ
framework  ||| S:1149 E:1159 ||| NN
for  ||| S:1159 E:1163 ||| IN
future  ||| S:1163 E:1170 ||| JJ
development  ||| S:1170 E:1182 ||| NN
of  ||| S:1182 E:1185 ||| IN
temsirolimus  ||| S:1185 E:1198 ||| NN
and  ||| S:1198 E:1202 ||| CC
other  ||| S:1202 E:1208 ||| JJ
mTOR  ||| S:1208 E:1213 ||| JJ
inhibitors ||| S:1213 E:1223 ||| NN
.  ||| S:1223 E:1225 ||| .
